Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,...
Reexamination Certificate
2005-12-29
2008-10-07
Yu, Misook (Department: 1642)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
C530S387100
Reexamination Certificate
active
07431923
ABSTRACT:
This invention relates to the diagnosis and treatment of cancerous diseases, particularly to the mediation of cytotoxicity of tumor cells; and most particularly to the use of cancerous disease modifying antibodies (CDMAB), optionally in combination with one or more chemotherapeutic agents, as a means for initiating the cytotoxic response. The invention further relates to binding assays which utilize the CDMABs of the instant invention.
REFERENCES:
patent: 4861581 (1989-08-01), Epstein et al.
patent: 5171665 (1992-12-01), Hellstrom et al.
patent: 5296348 (1994-03-01), Rackowicz-Szulczynsk
patent: 5484596 (1996-01-01), Hanna, Jr. et al.
patent: 5693763 (1997-12-01), Codington et al.
patent: 5750102 (1998-05-01), Eisenbach et al.
patent: 5780033 (1998-07-01), Torchillin et al.
patent: 5783186 (1998-07-01), Arakawa et al.
patent: 5849876 (1998-12-01), Linsley et al.
patent: 5869045 (1999-02-01), Hellstrom et al.
patent: 5869268 (1999-02-01), Kudo et al.
patent: 6180357 (2001-01-01), Young et al.
patent: 6245898 (2001-06-01), Testa et al.
patent: 6783961 (2004-08-01), Edwards et al.
patent: 6783969 (2004-08-01), Tang et al.
patent: 2002/0102638 (2002-08-01), Rosen et al.
patent: 2003/0055220 (2003-03-01), Legrain
patent: 2003/0148408 (2003-08-01), Frantz et al.
patent: 2004/0105816 (2004-06-01), Young et al.
patent: 2004/0141913 (2004-07-01), Young et al.
patent: 2004/0141915 (2004-07-01), Young et al.
patent: 2004/0197328 (2004-10-01), Young et al.
patent: 2004/0198651 (2004-10-01), Klammer et al.
patent: 1326951 (2001-12-01), None
patent: 1326962 (2001-12-01), None
patent: 1351054 (2002-05-01), None
patent: 1364803 (2002-08-01), None
patent: 1 033 401 (2000-06-01), None
patent: WO 99/66027 (1999-12-01), None
patent: WO 00/05918 (2000-02-01), None
patent: WO 00/55180 (2000-09-01), None
patent: WO 01/75177 (2001-10-01), None
patent: WO 02/00677 (2002-01-01), None
patent: WO 02/055551 (2002-07-01), None
patent: WO 02/057303 (2002-07-01), None
patent: WO 02/070539 (2002-09-01), None
patent: WO 03/016475 (2003-02-01), None
patent: WO 03/057160 (2003-07-01), None
patent: WO 03/068268 (2003-08-01), None
patent: WO 03/070902 (2003-08-01), None
patent: WO 03/086456 (2003-10-01), None
patent: WO 2004/041170 (2004-05-01), None
Didrik and Winter (Jun. 13, 2006, PNAS, 103(24):9172-9177).
M. Adachi et al, “Novel staging protocol for non-small-cell lung cancers according to MRP-1/CD9 and KAII/CD82 gene expression”, J. Clin. Oncol., 16(4):1397-1406 (Apr. 1998).
G. Andreola et al, “Induction of lymphocyte apoptosis by tumor cell secretion of FasL-bearing microvesicles”, J. Exp. Med., 195(10):1303-1316 (May 2002).
B. Atkinson et al, “Monoclonal antibody to a highly glycosylated protein reacts in fixed tissue with melanoma and other tumors”, Hybridoma, 4(3):243-255 (1985).
D. Azorsa et al, “A general approach to the generation of monoclonal antibodies against members of the tetraspanin superfamily using recombinant GST fusion proteins”, J. Immunol. Meth., 229:35-48 (1999).
M. Barrio et al, “A new epitope on human melanoma-associated antigen CD63/ME491 expressed by both primary and metastatic melanoma”, Hybridoma, 17(4):355-364 (1998).
M. Barrio et al, “Monoclonal antibody FC-5.01, directed against CD63 antigen, is internalized into cytoplasmic vesicles in the IIB-BR-G human breast cancer cell line”, Hybridoma, 17(6):517-523 (1998).
F. Berditchevski et al, “Characterization of integrin-tetraspanin adhesion complexes: role of tetraspanins in integrin signaling”, J. Cell Biol., 146(2):477-492 (Jul. 1999).
F. Berditchevski et al, “A novel link between integrins, transmembrane-4 superfamily proteins (CD63 and CD81), and phosphatidylinositol 4-kinase”, J. Biol. Chem., 272(5):2595-2598 (Jan. 1997).
F. Berditchevski et al, “Specific association of CD63 with the VLA-3 and VLA-6 integrins”, J. Biol. Chem., 270(30):17784-11790 (Jul. 1995).
D. Blakey et al, “Antitumor activity of the novel vascular targeting agent ZD6126 in a panel of tumor models”, Clinical Cancer Research, 8:1974-1983 (Jun. 2002).
A. Carmo et al, “Association of the transmembrane 4 superfamily molecule CD53 with a tyrosine phosphatase activity”, Eur. J. Immunol., 25:2090-2095 (1995).
C. Claas et al, “Evaluation of prototype transmembrane 4 superfamily protein complexes and their relation to lipid rafts”, J. Biol. Chem., 276(11):7974-7984 (Mar. 2001).
D. Demetrick et al, “ME491 melanoma-associated glycoprotein family: antigenic identity of ME491, NKI/C-3, neuroglandular antigen (NGA), and CD63 proteins”, J. Natl Cancer Inst, 84(6):422-429 (Mar. 1992).
G. Eckhardt et al, “Developmental therapeutics: successes and failures of clinical trial designs of targeted compounds”, In American Society of Clinical Oncology, pp. 209-219 (2003).
A. Engering et al, “Association of distinct tetraspanins with MHC class II molectules at different subcellular locations in human immature dendritic cells”, International Immunology, 13(2):127-134 (2001).
J-M. Escola et al, “Selective enrichment of tetraspan proteins on the internal vesicles of multivesicular endosomes and on exosomes secreted by human B-lymphocytes”, J. Biol. Chem., 273(32):20121-20127 (Aug. 1998).
S. Guichard et al, “Schedule-dependent activity of topotecan in OVCAR-3 ovarian carcinoma xenograft: pharmacokinetic and pharmacodynamic evaluation”, Clinical Cancer Research, 7:3222-3228 (Oct. 2001).
N. Guilbaud et al, “Marked antitumor activity of a new potent acronycine derivative in orthotopic models of human solid tumors”, Clinical Cancer Research, 7:2573-2580 (Aug. 2001).
C. Hammond et al, “The tetraspan protein CD82 is a resident of MHC class II compartments where it associates with HLA-DR, -DM, and -DO molecules”, J. Immunol, 161:3282-3291 (1998).
J. Hildreth et al, “Characterization of a novel self-associating Mr 40,000 platelet glycoprotein”, Blood, 77(1):121-132 (Jan. 1991).
S. Hirschfeld et al, “Oncology drug development: United States Food and Drug Administration perspective”, Critical Reviews in Oncology/Hematology, 42:137-143 (2002).
H. Hotta et al, “Genomic structure of the ME491/CD63 antigen gene and functional analysis of the 5′-flanking regulatory sequences”, Biochem Biophys Res Comm, 185(1):436-442 (May 1992).
H. Hotta et al, “Molecular cloning and characterization of an antigen associated with early stages of melanoma tumor progression”, Cancer Research, 48:2955-2962 (Jun. 1988).
H. Hotta et al, “Overexpression of the human melanoma-associated antigen ME491 patially suppresses in vivo malignant phenotypes of H-ras-transformed NIH3T3 cells in athymic nude mice”, Melanoma Research, 1:125-132 (1991).
C. Huang et al, “Correlation of reduction in MRP-1/CD9 and KAI1/CD82 expression with recurrences in breast cancer patients”, Am J Pathol, 153(3):973-983 (Sep. 1998).
H-I. Jang et al, “A decrease in the expression of CD63 tetraspanin protein elevates invasive potential of human melanoma cells”, Experimental and Molecular Medicine, 35(4):317-323 (Aug. 2003).
C. Joyner et al, “Identification and enrichment of human osteoprogenitor cells by using differentiation stage-specific monoclonal antibodies”, Bone, 21(1):1-6 (Jul. 1997).
T. Karpanen et al, “Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth”, Cancer Research, 61:1786-1790 (Mar. 2001).
S. Kennel et al, “Monoclonal antibody to rat CD63 detects different molecular forms in rat tissue”, Hybridoma, 17(6):509-515 (1998).
G. Klement et al, “Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts”, Clinical Cancer Research, 8:221-232 (Jan. 2002).
T. Kobayashi et al, “T
da Cruz Luis A. G.
Findlay Helen P.
Hahn Susan E.
Young David S. F.
Aeder Sean E
Arius Research Inc.
McHale & Slavin P.A.
Yu Misook
LandOfFree
Cytotoxicity mediation of cells evidencing surface... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cytotoxicity mediation of cells evidencing surface..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cytotoxicity mediation of cells evidencing surface... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3999126